companies

Splice Bio

Founded 2012
Employees 15+
Primary contact
Parc Científic de Barcelona
Baldiri Reixac, 10
08028 Barcelona
Catalonia
Spain
+34 934 02 04 56
Links
https://splice.bio/
Sections
Formerly called ProteoDesign, SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Its platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. In this novel approach, engineered inteins catalyze highly efficient protein trans-splicing to reconstitute the desired full-length therapeutic protein in vivo.
Select partners: Cystic Fibrosis Foundation.
Founded 2012
Employees 15+
Primary contact
Parc Científic de Barcelona
Baldiri Reixac, 10
08028 Barcelona
Catalonia
Spain
+34 934 02 04 56
Links
https://splice.bio/
Sections

Funding 💰

Total $58.8M
Last round 🔗 €50M
Series A
February 16, 2022.
Select investors UCB Ventures, Ysios Capital, New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund, Asabys Partners, Caixa Capital

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving the problem: Adeno-associated viruses (AAV) are the gene therapy vector of choice for the treatment of genetic diseases. However, their small packaging capacity is a major challenge for the development of novel gene therapies. SpliceBio's Protein Splicing platform aims to address this major limitation to enable the efficient delivery of large genes using AAV vectors.
  • Proprietary tech: Engineered split inteins lie at the core of SpliceBio's platform, but it has also developed additional proprietary technologies in-house that altogether conform its Protein Splicing platform. 🔗
  • Multiple gene therapies: SpliceBio's lead program is in Stargardt disease, the most common inherited retinal disorder caused by mutations in a single gene, ABCA4, which at 6.8 kb is too large for single AAV vectors. In addition, the company is developing gene therapy programs in several other therapeutic areas where the platform has also been validated. 🔗
  • Setup for growth: In January 2021, Splice Bio appointed Jean-Philippe Combal as Chairman of the Board of Directors. Currently serving as a CEO & Co-founder of Vivet Therapeutics, he is a senior executive and biotech entrepreneur who has built companies in the biotech industry from creation with significant fund raising with VCs, IPO and M&A.

Awards & Recognitions 🏆

  • 2022 AseBio Investor Day Award 🔗

Quotes 💬

“
We are delighted to support SpliceBio in the development of its innovative platform to create treatments for patients suffering from genetic diseases not currently addressable by existing gene therapy approaches.
— Erica Whittaker, Vice President and Head of UCB Ventures 🔗
“
We are proud to have been involved with the Company since its early days and are very impressed with the progress achieved to date. SpliceBio's platform represents an unprecedented opportunity to expand the universe of diseases that can be addressed with gene therapy. This financing is also a testament to the growing potential of the biotech hub in Barcelona.
— Joël Jean-Mairet, Managing Partner at Ysios Capital 🔗
“
We are very pleased to back this team, building on the founders' early-stage research at Princeton's Muir Laboratory to develop SpliceBio into a world leading gene therapy player. We believe SpliceBio's innovative approach to maximizing the capacity of AAV vectors has the potential to make a meaningful impact in the delivery of much needed gene therapies, and we look forward to supporting the Company through its next stages of growth.
— Ed Mathers, General Partner at NEA 🔗
Last update: January 13, 2023